#United States #cancer therapy #Tampa #Immuno-Oncology #TuHURA Biosciences

TuHURA Biosciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

TuHURA Biosciences, Inc. (NASDAQ:HURA), a leading company in the field of immuno-oncology, has announced an important presentation scheduled during the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Dr. James Bianco, the President and CEO, will represent the company on February 26, 2026, at 3:20 PM ET. This event positions TuHURA at the forefront of the battle against cancer, especially focusing on innovative therapies that tackle resistance issues often seen in conventional cancer treatments.

The upcoming presentation will provide a platform for TuHURA to elucidate its pioneering work in developing novel therapeutics aimed at overcoming resistance to cancer immunotherapy. The company’s commitment is reflected in its Phase 3 clinical trials, which are designed to address one of the significant challenges in cancer treatment: the failure of immunotherapies in a substantial number of patients due to primary and acquired resistance.

TuHURA’s lead product, IFx-2.0, is an innate immune agonist aimed at counteracting primary resistance to checkpoint inhibitors. Currently, the company is advancing a pivotal Phase 3 registration trial identifying the efficacy of IFx-2.0 when used in conjunction with Keytruda® (pembrolizumab) in treating advanced or metastatic Merkel Cell Carcinoma—a rare and aggressive skin cancer. Patients will be enrolled in a randomized placebo-controlled study to assess how well this innovative therapy performs compared to Keytruda® alone.

In a recent strategic move, TuHURA expanded its portfolio by acquiring TBS-2025 through its merger with Kineta Inc. This product is a VISTA inhibiting monoclonal antibody progressing into Phase 2 development for treatment options in patients with mutant NPM1 relapsed/refractory Acute Myeloid Leukemia (AML).

The integration of Delta Opioid Receptor technology into their research framework is another significant milestone for TuHURA. By developing first-in-class, bi-specific antibody-drug conjugates and antibody peptide conjugates that specifically target Myeloid Derived Suppressor Cells, they aim to mitigate their immunosuppressive effects on tumors. This advancement could lead to a more robust immune response, helping to prevent T-cell exhaustion and acquired resistance to existing cancer therapies.

The forward-thinking approach by TuHURA in immuno-oncology highlights its commitment to innovation and patient-centered care. By presenting at the Oppenheimer Healthcare Conference, the company not only seeks to engage with stakeholders and investors but also to spread awareness about the critical advancements in cancer treatment solutions.

For investors and those interested in attending, the live and archived webcast of Dr. Bianco’s presentation will be accessible via TuHURA's corporate website, ensuring widespread information dissemination and engagement.

In summary, the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference stands as a testament to TuHURA Biosciences' efforts to advance the field of immuno-oncology and address pressing cancer treatment challenges. For more detailed information about their innovative therapies, visit TuHURA's corporate website.

Stay connected with TuHURA through their social media platforms, including Facebook, X, and LinkedIn, for the latest updates on their research and developments.